miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source documentYahoo Finance· July 26, 2026

AT&T Beat on Earnings, Announced a $10 Billion Buyback, and Still Trades at 8 Times Earnings With a 4.6% Yield.

View original at finance.yahoo.com
AT&T Beat on Earnings, Announced a $10 Billion Buyback, and Still Trades at 8 Times Earnings With a 4.6% Yield. The market has spent years treating AT&T (NYSE: T) as a bond that happens to trade on an exchange…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

Data points we hold from this source

AT&T Inc. · stock price24.13 USD
AT&T Inc. · 52 week high29.79 USD
AT&T Inc. · pe ratio8 ratio
AT&T Inc. · fixed wireless customers added279000 customers
AT&T Inc. · adjusted ebitda margin39.1 percent
AT&T Inc. · planned shareholder returns total18 USD
AT&T Inc. · annual dividend total7.6 USD
AT&T Inc. · free cash flow4.7 USD
AT&T Inc. · fiber locations passed38.6 millions
AT&T Inc. · fiber customers added367000 customers
AT&T Inc. · diluted eps continuing ops0.66 USD_per_share
AT&T Inc. · internet customers added646000 customers
AT&T Inc. · annual dividend per share1.11 USD
AT&T Inc. · eps0.65 USD_per_share
AT&T Inc. · shares outstanding6.9 billions
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
AT&T Beat on Earnings, Announced a $10 Billion Buyback, and Still Trades at 8 Times Earnings With a 4.6% Yield. — Source | Via News | es.VIA.NEWS